This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desmet, W. Articles by Piessens, J. Search for Related Content PubMed PubMed Citation Articles by Desmet, W. Articles by Piessens, J.

Circulation, Vol 89, 385-392, Copyright © 1994 by American Heart Association

ARTICLES

Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty

W Desmet, M Vrolix, I De Scheerder, J Van Lierde, JL Willems and J Piessens
Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.

BACKGROUND: Several angiotensin-converting enzyme inhibitors have antiproliferative effects in a rat model after carotid artery balloon injury. METHODS AND RESULTS: We conducted a randomized, double-blind, placebo-controlled trial to assess the effect of fosinopril, a novel angiotensin-converting enzyme inhibitor, in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Patients received fosinopril or matched placebo 10 mg at least 18 hours before PTCA, 20 mg at least 4 hours before PTCA, and 40 mg daily for 6 months. In addition, all patients received aspirin. Coronary angiograms before PTCA and immediately after PTCA as well as at 6-month follow-up were quantitatively analyzed. A total of 509 patients were recruited. The final per-protocol population consisted of 153 fosinopril-treated and 151 placebo-treated patients. Restenosis rates according to the National Heart, Lung, and Blood Institute criterion 4 (loss of > or = 50% of the initial gain [primary end point]) were 45.7% and 40.7% in the fosinopril and control groups, respectively (not significant). The respective mean differences in minimal coronary luminal diameter between post-PTCA and follow-up angiograms were -0.59 +/- 0.71 mm and - 0.51 +/- 0.67 mm (not significant). Clinical events during the 6-month follow-up period, analyzed on an on-treatment basis, were ranked according to the most serious event. The respective numbers in the fosinopril and the control groups were for death, 0 and 0; myocardial infarction, 0 and 0; coronary artery bypass graft surgery, 1 and 3; repeat PTCA, 35 and 35; recurrent signs of ischemia necessitating early repeat coronary angiography and managed medically, 6 and 7; and none of the above, 111 and 106. All these differences were significant. CONCLUSIONS: Administration of fosinopril in a dose of 40 mg daily during 6 months after PTCA does not prevent restenosis and has no effect on overall clinical outcome.

This article has been cited by other articles:

				N. Danchin, M. Cucherat, C. Thuillez, E. Durand, Z. Kadri, and P. G. Steg Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials. Arch Intern Med, April 10, 2006; 166(7): 787 - 796. [Abstract] [Full Text] [PDF]

				E. Jorgensen, H. Kelbaek, S. Helqvist, G. V. H. Jensen, K. Saunamaki, J. Kastrup, O. Havndrup, H. Bundgaard, J. Kyst Madsen, M. Christiansen, et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1434 - 1439. [Abstract] [Full Text] [PDF]

				M.Y Salame, S Verheye, I.R Crocker, N.A.F Chronos, K.A Robinson, and S.B King III Intracoronary radiation therapy Eur. Heart J., April 2, 2001; 22(8): 629 - 647. [PDF]

				S. MacMahon, N. Sharpe, G. Gamble, A. Clague, C. Ni Mhurchu, T. Clark, H. Hart, J. Scott, H. White, and PART-2 Collaborative Research Group Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease J. Am. Coll. Cardiol., August 1, 2000; 36(2): 438 - 443. [Abstract] [Full Text] [PDF]

				P. Colson, F. Ryckwaert, and P. Coriat Renin Angiotensin System Antagonists and Anesthesia Anesth. Analg., November 1, 1999; 89(5): 1143 - 1143. [Full Text] [PDF]

				A. Lucas, E. Dai, L.-Y. Liu, and P. N Nation Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy Cardiovasc Res, April 1, 1998; 38(1): 237 - 246. [Abstract] [Full Text] [PDF]

				I. De Scheerder, K. Wang, K. Wilczek, D. Meuleman, R. Van Amsterdam, G. Vogel, J. Piessens, and F. Van de Werf Experimental Study of Thrombogenicity and Foreign Body Reaction Induced by Heparin-Coated Coronary Stents Circulation, March 18, 1997; 95(6): 1549 - 1553. [Abstract] [Full Text]

				W. R. Huckle, M. D. Drag, W. R. Acker, M. Powers, R. C. McFall, D. J. Holder, T. Fujita, I. I. Stabilito, D. Kim, D. L. Ondeyka, et al. Effects of Subtype-Selective and Balanced Angiotensin II Receptor Antagonists in a Porcine Coronary Artery Model of Vascular Restenosis Circulation, March 1, 1996; 93(5): 1009 - 1019. [Abstract] [Full Text]

				Y. Furukawa, A. Matsumori, T. Hirozane, and S. Sasayama Angiotensin II Receptor Antagonist TCV-116 Reduces Graft Coronary Artery Disease and Preserves Graft Status in a Murine Model : A Comparative Study With Captopril Circulation, January 15, 1996; 93(2): 333 - 339. [Abstract] [Full Text]

				F. M. van Bockxmeer, C. D. S. Mamotte, F. A. Gibbons, V. Burke, and R. R. Taylor Angiotensin-Converting Enzyme and Apolipoprotein E Genotypes and Restenosis After Coronary Angioplasty Circulation, October 15, 1995; 92(8): 2066 - 2071. [Abstract] [Full Text]